Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
Get more information about the TH4000 Trial.